100TH GENERAL ASSEMBLY

State of Illinois

2017 and 2018

HB3910

by Rep. Kathleen Willis

SYNOPSIS AS INTRODUCED:

720 ILCS 570/102	from Ch. 56 1/2, par. 1102
720 ILCS 570/312	from Ch. 56 1/2, par. 1312

Amends the Illinois Controlled Substances Act. Provides that emergency medical services personnel may administer Schedule II, III, IV, or V controlled substances to a person in the scope of their employment without a written, electronic, or oral prescription of a prescriber. Defines emergency medical services personnel. Includes "emergency medical services personnel" in the definition of "practitioner" under the Act.

LRB100 10675 RLC 20899 b

AN ACT concerning criminal law.

Be it enacted by the People of the State of Illinois, 2 represented in the General Assembly: 3

The Illinois Controlled Substances Act is 4 Section 5. amended by changing Sections 102 and 312 as follows: 5

(720 ILCS 570/102) (from Ch. 56 1/2, par. 1102) 6

7 Sec. 102. Definitions. As used in this Act, unless the 8 context otherwise requires:

9 (a) "Addict" means any person who habitually uses any drug, chemical, substance or dangerous drug other than alcohol so as 10 to endanger the public morals, health, safety or welfare or who 11 is so far addicted to the use of a dangerous drug or controlled 12 substance other than alcohol as to have lost the power of self 13 14 control with reference to his or her addiction.

"Administer" means the direct application of 15 (b) а 16 controlled substance, whether by injection, inhalation, 17 ingestion, or any other means, to the body of a patient, research subject, or animal (as defined by the Humane 18 19 Euthanasia in Animal Shelters Act) by:

20 (1) a practitioner (or, in his or her presence, by his 21 or her authorized agent),

22 (2) the patient or research subject pursuant to an order, or 23

1

HB3910 - 2 - LRB100 10675 RLC 20899 b

1 2

(3) a euthanasia technician as defined by the Humane Euthanasia in Animal Shelters Act.

3 (c) "Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, 4 5 dispenser, prescriber, or practitioner. It does not include a 6 common or contract carrier, public warehouseman or employee of 7 the carrier or warehouseman.

8 (c-1) "Anabolic Steroids" means any drug or hormonal 9 substance, chemically and pharmacologically related to 10 testosterone (other than estrogens, progestins, 11 corticosteroids, and dehydroepiandrosterone), and includes:

12

22

(i) 3[beta], 17-dihydroxy-5a-androstane,

(ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, 13

14 (iii) 5[alpha]-androstan-3,17-dione,

15 (iv) 1-androstenediol (3[beta],

16 17[beta]-dihydroxy-5[alpha]-androst-1-ene),

(v) 1-androstenediol (3[alpha], 17

17[beta]-dihydroxy-5[alpha]-androst-1-ene), 18

(vi) 4-androstenediol 19

20 (3[beta],17[beta]-dihydroxy-androst-4-ene),

(vii) 5-androstenediol 21

(3[beta],17[beta]-dihydroxy-androst-5-ene),

23 (viii) 1-androstenedione

24 ([5alpha]-androst-1-en-3,17-diome),

25 (ix) 4-androstenedione

26 (androst-4-en-3,17-dione),

1	(x) 5-androstenedione
2	(androst-5-en-3,17-dione),
3	(xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-
4	hydroxyandrost-4-en-3-one),
5	(xii) boldenone (17[beta]-hydroxyandrost-
6	1,4,-diene-3-one),
7	(xiii) boldione (androsta-1,4-
8	diene-3,17-dione),
9	(xiv) calusterone (7[beta],17[alpha]-dimethyl-17
10	[beta]-hydroxyandrost-4-en-3-one),
11	(xv) clostebol (4-chloro-17[beta]-
12	hydroxyandrost-4-en-3-one),
13	(xvi) dehydrochloromethyltestosterone (4-chloro-
14	17[beta]-hydroxy-17[alpha]-methyl-
15	androst-1,4-dien-3-one),
16	(xvii) desoxymethyltestosterone
17	(17[alpha]-methyl-5[alpha]
18	-androst-2-en-17[beta]-ol)(a.k.a., madol),
19	(xviii) [delta]1-dihydrotestosterone (a.k.a.
20	'1-testosterone') (17[beta]-hydroxy-
21	5[alpha]-androst-1-en-3-one),
22	(xix) 4-dihydrotestosterone (17[beta]-hydroxy-
23	androstan-3-one),
24	(xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-
25	5[alpha]-androstan-3-one),
26	(xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-

1	hydroxyestr-4-ene),
2	(xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-
3	1[beta],17[beta]-dihydroxyandrost-4-en-3-one),
4	(xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],
5	17[beta]-dihydroxyandrost-1,4-dien-3-one),
6	(xxiv) furazabol (17[alpha]-methyl-17[beta]-
7	hydroxyandrostano[2,3-c]-furazan),
8	(xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one)
9	(xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-
10	androst-4-en-3-one),
11	(xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-
12	dihydroxy-estr-4-en-3-one),
13	(xxviii) mestanolone (17[alpha]-methyl-17[beta]-
14	hydroxy-5-androstan-3-one),
15	(xxix) mesterolone (lamethyl-17[beta]-hydroxy-
16	[5a]-androstan-3-one),
17	(xxx) methandienone (17[alpha]-methyl-17[beta]-
18	hydroxyandrost-1,4-dien-3-one),
19	(xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-
20	dihydroxyandrost-5-ene),
21	(xxxii) methenolone (1-methyl-17[beta]-hydroxy-
22	5[alpha]-androst-1-en-3-one),
23	(xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-
24	dihydroxy-5a-androstane),
25	(xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy
26	-5a-androstane),

	HB3910 - 5 - LRB100 10675 RLC 20899 b
1	(xxxv) 17[alpha]-methyl-3[beta],17[beta]-
2	dihydroxyandrost-4-ene),
3	(xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-
4	<pre>methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),</pre>
5	(xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-
6	hydroxyestra-4,9(10)-dien-3-one),
7	(xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-
8	hydroxyestra-4,9-11-trien-3-one),
9	(xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-
10	hydroxyandrost-4-en-3-one),
11	(xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-
12	hydroxyestr-4-en-3-one),
13	(xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
14	(17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-
15	androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl-
16	1-testosterone'),
17	(xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),
18	(xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-
19	dihydroxyestr-4-ene),
20	(xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-
21	dihydroxyestr-4-ene),
22	(xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-
23	dihydroxyestr-5-ene),
24	(xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-
25	dihydroxyestr-5-ene),
26	(m) (m)

(xlvii) 19-nor-4,9(10)-androstadienedione

	HB3910 - 6 - LRB100 10675 RLC 20899 b
1	(estra-4,9(10)-diene-3,17-dione),
2	(xlviii) 19-nor-4-androstenedione (estr-4-
3	en-3,17-dione),
4	(xlix) 19-nor-5-androstenedione (estr-5-
5	en-3,17-dione),
6	(l) norbolethone (13[beta], 17a-diethyl-17[beta]-
7	hydroxygon-4-en-3-one),
8	(li) norclostebol (4-chloro-17[beta]-
9	hydroxyestr-4-en-3-one),
10	(lii) norethandrolone (17[alpha]-ethyl-17[beta]-
11	hydroxyestr-4-en-3-one),
12	(liii) normethandrolone (17[alpha]-methyl-17[beta]-
13	hydroxyestr-4-en-3-one),
14	(liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-
15	2-oxa-5[alpha]-androstan-3-one),
16	(lv) oxymesterone (17[alpha]-methyl-4,17[beta]-
17	dihydroxyandrost-4-en-3-one),
18	(lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-
19	17[beta]-hydroxy-(5[alpha]-androstan-3-one),
20	(lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-
21	(5[alpha]-androst-2-eno[3,2-c]-pyrazole),
22	(lviii) stenbolone (17[beta]-hydroxy-2-methyl-
23	(5[alpha]-androst-1-en-3-one),
24	(lix) testolactone (13-hydroxy-3-oxo-13,17-
25	secoandrosta-1,4-dien-17-oic
26	acid lactone),

```
HB3910
```

1	(lx) testosterone (17[beta]-hydroxyandrost-
2	4-en-3-one),
3	(lxi) tetrahydrogestrinone (13[beta], 17[alpha]-
4	diethyl-17[beta]-hydroxygon-
5	4,9,11-trien-3-one),
6	(lxii) trenbolone (17[beta]-hydroxyestr-4,9,

7

11-trien-3-one).

8 Any person who is otherwise lawfully in possession of an 9 anabolic steroid, or who otherwise lawfully manufactures, 10 distributes, dispenses, delivers, or possesses with intent to 11 deliver an anabolic steroid, which anabolic steroid is 12 expressly intended for and lawfully allowed to be administered 13 through implants to livestock or other nonhuman species, and which is approved by the Secretary of Health and Human Services 14 for such administration, and which the person intends to 15 16 administer or have administered through such implants, shall 17 not be considered to be in unauthorized possession or to unlawfully manufacture, distribute, dispense, deliver, or 18 possess with intent to deliver such anabolic steroid for 19 20 purposes of this Act.

(d) "Administration" means the Drug Enforcement
Administration, United States Department of Justice, or its
successor agency.

(d-5) "Clinical Director, Prescription Monitoring Program"
 means a Department of Human Services administrative employee
 licensed to either prescribe or dispense controlled substances

who shall run the clinical aspects of the Department of Human
 Services Prescription Monitoring Program and its Prescription
 Information Library.

(d-10) "Compounding" means the preparation and mixing of 4 5 components, excluding flavorings, (1) as the result of a prescriber's prescription drug order or initiative based on the 6 7 prescriber-patient-pharmacist relationship in the course of 8 professional practice or (2) for the purpose of, or incident 9 to, research, teaching, or chemical analysis and not for sale 10 or dispensing. "Compounding" includes the preparation of drugs 11 or devices in anticipation of receiving prescription drug 12 orders based on routine, regularly observed dispensing patterns. Commercially available products may be compounded 13 for dispensing to individual patients only if both of the 14 15 following conditions are met: (i) the commercial product is not 16 reasonably available from normal distribution channels in a 17 timely manner to meet the patient's needs and (ii) the prescribing practitioner has requested that the drug be 18 19 compounded.

20 (e) "Control" means to add a drug or other substance, or 21 immediate precursor, to a Schedule whether by transfer from 22 another Schedule or otherwise.

(f) "Controlled Substance" means (i) a drug, substance, immediate precursor, or synthetic drug in the Schedules of Article II of this Act or (ii) a drug or other substance, or immediate precursor, designated as a controlled substance by the Department through administrative rule. The term does not include distilled spirits, wine, malt beverages, or tobacco, as those terms are defined or used in the Liquor Control Act of 1934 and the Tobacco Products Tax Act of 1995.

5

(f-5) "Controlled substance analog" means a substance:

6 (1) the chemical structure of which is substantially 7 similar to the chemical structure of a controlled substance 8 in Schedule I or II;

9 (2)stimulant, which has а depressant, or 10 hallucinogenic effect on the central nervous system that is 11 substantially similar to or greater than the stimulant, 12 depressant, or hallucinogenic effect on the central nervous system of a controlled substance in Schedule I or 13 14 II; or

15 (3) with respect to a particular person, which such 16 represents or intends to have a stimulant, person 17 depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater 18 19 than the stimulant, depressant, or hallucinogenic effect 20 on the central nervous system of a controlled substance in Schedule I or II. 21

(g) "Counterfeit substance" means a controlled substance, which, or the container or labeling of which, without authorization bears the trademark, trade name, or other identifying mark, imprint, number or device, or any likeness thereof, of a manufacturer, distributor, or dispenser other

1 than the person who in fact manufactured, distributed, or 2 dispensed the substance.

3 (h) "Deliver" or "delivery" means the actual, constructive 4 or attempted transfer of possession of a controlled substance, 5 with or without consideration, whether or not there is an 6 agency relationship.

7 (i) "Department" means the Illinois Department of Human
8 Services (as successor to the Department of Alcoholism and
9 Substance Abuse) or its successor agency.

10 (j) (Blank).

11 (k) "Department of Corrections" means the Department of12 Corrections of the State of Illinois or its successor agency.

(1) "Department of Financial and Professional Regulation"
means the Department of Financial and Professional Regulation
of the State of Illinois or its successor agency.

16 (m) "Depressant" means any drug that (i) causes an overall 17 depression of central nervous system functions, (ii) causes impaired consciousness and awareness, and (iii) can be 18 19 habit-forming or lead to a substance abuse problem, including 20 but not limited to alcohol, cannabis and its active principles 21 and their analogs, benzodiazepines and their analogs, 22 barbiturates and their analogs, opioids (natural and 23 synthetic) and their analogs, and chloral hydrate and similar sedative hypnotics. 24

25 (n) (Blank).

26

(o) "Director" means the Director of the Illinois State

HB3910 - 11 - LRB100 10675 RLC 20899 b

1 Police or his or her designated agents.

(p) "Dispense" means to deliver a controlled substance to an ultimate user or research subject by or pursuant to the lawful order of a prescriber, including the prescribing, administering, packaging, labeling, or compounding necessary to prepare the substance for that delivery.

7

(q) "Dispenser" means a practitioner who dispenses.

8 (r) "Distribute" means to deliver, other than by 9 administering or dispensing, a controlled substance.

10

(s) "Distributor" means a person who distributes.

11 (t) "Drug" means (1) substances recognized as drugs in the 12 official United States Pharmacopoeia, Official Homeopathic Pharmacopoeia of the United States, or official National 13 Formulary, or any supplement to any of them; (2) substances 14 15 intended for use in diagnosis, cure, mitigation, treatment, or 16 prevention of disease in man or animals; (3) substances (other 17 than food) intended to affect the structure of any function of the body of man or animals and (4) substances intended for use 18 as a component of any article specified in clause (1), (2), or 19 20 (3) of this subsection. It does not include devices or their 21 components, parts, or accessories.

(t-3) "Electronic health record" or "EHR" means an electronic record of health-related information on an individual that is created, gathered, managed, and consulted by authorized health care clinicians and staff.

26 (t-4) "Emergency medical services personnel" has the

1 <u>meaning ascribed to it in the Emergency Medical Services (EMS)</u> 2 Systems Act.

(t-5) "Euthanasia agency" means an entity certified by the 3 Department of Financial and Professional Regulation for the 4 5 purpose of animal euthanasia that holds an animal control facility license or animal shelter license under the Animal 6 Welfare Act. A euthanasia agency is authorized to purchase, 7 store, possess, and utilize Schedule II nonnarcotic and 8 9 Schedule III nonnarcotic drugs for the sole purpose of animal 10 euthanasia.

11 (t-10) "Euthanasia drugs" means Schedule II or Schedule III 12 substances (nonnarcotic controlled substances) that are used 13 by a euthanasia agency for the purpose of animal euthanasia.

(u) "Good faith" means the prescribing or dispensing of a 14 15 controlled substance by a practitioner in the regular course of 16 professional treatment to or for any person who is under his or 17 her treatment for a pathology or condition other than that individual's physical or psychological dependence upon or 18 19 addiction to a controlled substance, except as provided herein: and application of the term to a pharmacist shall mean the 20 21 dispensing of а controlled substance pursuant to the 22 prescriber's order which in the professional judgment of the 23 pharmacist is lawful. The pharmacist shall be quided by accepted professional standards including, but not limited to 24 25 the following, in making the judgment:

26

(1) lack of consistency of prescriber-patient

1 relationship,

2 (2) frequency of prescriptions for same drug by one
3 prescriber for large numbers of patients,

4

(3) quantities beyond those normally prescribed,

5 (4) unusual dosages (recognizing that there may be 6 clinical circumstances where more or less than the usual 7 dose may be used legitimately),

8 (5) unusual geographic distances between patient,
9 pharmacist and prescriber,

10

(6) consistent prescribing of habit-forming drugs.

11 (u-0.5) "Hallucinogen" means a drug that causes markedly 12 altered sensory perception leading to hallucinations of any 13 type.

14 (u-1) "Home infusion services" means services provided by a 15 pharmacy in compounding solutions for direct administration to 16 a patient in a private residence, long-term care facility, or 17 hospice setting by means of parenteral, intravenous, 18 intramuscular, subcutaneous, or intraspinal infusion.

19 (u-5) "Illinois State Police" means the State Police of the20 State of Illinois, or its successor agency.

21

(v) "Immediate precursor" means a substance:

(1) which the Department has found to be and by rule designated as being a principal compound used, or produced primarily for use, in the manufacture of a controlled substance;

26

(2) which is an immediate chemical intermediary used or

likely to be used in the manufacture of such controlled
 substance; and

3 (3) the control of which is necessary to prevent,
4 curtail or limit the manufacture of such controlled
5 substance.

6 (w) "Instructional activities" means the acts of teaching, 7 educating or instructing by practitioners using controlled 8 substances within educational facilities approved by the State 9 Board of Education or its successor agency.

10 (x) "Local authorities" means a duly organized State,11 County or Municipal peace unit or police force.

12 (y) "Look-alike substance" means a substance, other than a 13 controlled substance which (1) by overall dosage unit 14 appearance, including shape, color, size, markings or lack 15 thereof, taste, consistency, or any other identifying physical 16 characteristic of the substance, would lead a reasonable person 17 to believe that the substance is a controlled substance, or (2) is expressly or impliedly represented to be a controlled 18 substance or is distributed under circumstances which would 19 20 lead a reasonable person to believe that the substance is a 21 controlled substance. For the purpose of determining whether 22 representations made or the circumstances of the the 23 distribution would lead a reasonable person to believe the substance to be a controlled substance under this clause (2) of 24 25 subsection (y), the court or other authority may consider the 26 following factors in addition to any other factor that may be

1 relevant:

2 (a) statements made by the owner or person in control
3 of the substance concerning its nature, use or effect;

4 (b) statements made to the buyer or recipient that the
5 substance may be resold for profit;

6 (c) whether the substance is packaged in a manner 7 normally used for the illegal distribution of controlled 8 substances;

9 (d) whether the distribution or attempted distribution 10 included an exchange of or demand for money or other 11 property as consideration, and whether the amount of the 12 consideration was substantially greater than the 13 reasonable retail market value of the substance.

14 Clause (1) of this subsection (y) shall not apply to a 15 noncontrolled substance in its finished dosage form that was 16 initially introduced into commerce prior to the initial 17 introduction into commerce of a controlled substance in its 18 finished dosage form which it may substantially resemble.

Nothing in this subsection (y) prohibits the dispensing or distributing of noncontrolled substances by persons authorized to dispense and distribute controlled substances under this Act, provided that such action would be deemed to be carried out in good faith under subsection (u) if the substances involved were controlled substances.

25 Nothing in this subsection (y) or in this Act prohibits the 26 manufacture, preparation, propagation, compounding, processing, packaging, advertising or distribution of a drug or drugs by any person registered pursuant to Section 510 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).

4 (y-1) "Mail-order pharmacy" means a pharmacy that is 5 located in a state of the United States that delivers, 6 dispenses or distributes, through the United States Postal 7 Service or other common carrier, to Illinois residents, any 8 substance which requires a prescription.

9 "Manufacture" means the production, preparation, (z) 10 propagation, compounding, conversion or processing of a 11 controlled substance other than methamphetamine, either 12 directly or indirectly, by extraction from substances of 13 independently by means of natural origin, or chemical 14 synthesis, or by a combination of extraction and chemical 15 synthesis, and includes any packaging or repackaging of the 16 substance or labeling of its container, except that this term 17 does not include:

(1) by an ultimate user, the preparation or compoundingof a controlled substance for his or her own use; or

20 (2) by a practitioner, or his or her authorized agent 21 under his or her supervision, the preparation, 22 compounding, packaging, or labeling of a controlled 23 substance:

(a) as an incident to his or her administering or
dispensing of a controlled substance in the course of
his or her professional practice; or

- 17 - LRB100 10675 RLC 20899 b

(b) as an incident to lawful research, teaching or 1 2 chemical analysis and not for sale.

(z-1) (Blank).

4

3

(z-5) "Medication shopping" means the conduct prohibited 5 under subsection (a) of Section 314.5 of this Act.

(z-10) "Mid-level practitioner" means (i) a physician 6 7 assistant who has been delegated authority to prescribe through 8 a written delegation of authority by a physician licensed to 9 practice medicine in all of its branches, in accordance with 10 Section 7.5 of the Physician Assistant Practice Act of 1987, 11 (ii) an advanced practice nurse who has been delegated 12 authority to prescribe through a written delegation of authority by a physician licensed to practice medicine in all 13 of its branches or by a podiatric physician, in accordance with 14 Section 65-40 of the Nurse Practice Act, (iii) an advanced 15 16 practice nurse certified as a nurse practitioner, nurse 17 midwife, or clinical nurse specialist who has been granted authority to prescribe by a hospital affiliate in accordance 18 with Section 65-45 of the Nurse Practice Act, (iv) an animal 19 20 euthanasia agency, or (v) a prescribing psychologist.

(aa) "Narcotic drug" means any of the following, whether 21 22 produced directly or indirectly by extraction from substances 23 of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical 24 25 synthesis:

26

(1) opium, opiates, derivatives of opium and opiates,

including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation; however the term marcotic drug" does not include the isoquinoline alkaloids of opium;

(2) (blank);

8

7

(3) opium poppy and poppy straw;

9 (4) coca leaves, except coca leaves and extracts of 10 coca leaves from which substantially all of the cocaine and 11 ecgonine, and their isomers, derivatives and salts, have 12 been removed;

13 (5) cocaine, its salts, optical and geometric isomers,
14 and salts of isomers;

15 (6) ecgonine, its derivatives, their salts, isomers,
16 and salts of isomers;

(7) any compound, mixture, or preparation which
contains any quantity of any of the substances referred to
in subparagraphs (1) through (6).

(bb) "Nurse" means a registered nurse licensed under theNurse Practice Act.

22 (cc) (Blank).

(dd) "Opiate" means any substance having an addiction forming or addiction sustaining liability similar to morphine or being capable of conversion into a drug having addiction forming or addiction sustaining liability.

(ee) "Opium poppy" means the plant of the species Papaver
 somniferum L., except its seeds.

3 (ee-5) "Oral dosage" means a tablet, capsule, elixir, or 4 solution or other liquid form of medication intended for 5 administration by mouth, but the term does not include a form 6 of medication intended for buccal, sublingual, or transmucosal 7 administration.

8 (ff) "Parole and Pardon Board" means the Parole and Pardon
9 Board of the State of Illinois or its successor agency.

10 (gg) "Person" means any individual, corporation, 11 mail-order pharmacy, government or governmental subdivision or 12 agency, business trust, estate, trust, partnership or 13 association, or any other entity.

(hh) "Pharmacist" means any person who holds a license or certificate of registration as a registered pharmacist, a local registered pharmacist or a registered assistant pharmacist under the Pharmacy Practice Act.

18 (ii) "Pharmacy" means any store, ship or other place in 19 which pharmacy is authorized to be practiced under the Pharmacy 20 Practice Act.

21 (ii-5) "Pharmacy shopping" means the conduct prohibited 22 under subsection (b) of Section 314.5 of this Act.

(ii-10) "Physician" (except when the context otherwise requires) means a person licensed to practice medicine in all of its branches.

26 (jj) "Poppy straw" means all parts, except the seeds, of

1 the opium poppy, after mowing.

2 (kk) "Practitioner" means a physician licensed to practice 3 medicine in all its branches, dentist, optometrist, podiatric physician, veterinarian, scientific investigator, pharmacist, 4 5 physician assistant, advanced practice nurse, licensed practical nurse, registered nurse, emergency medical services 6 7 personnel, hospital, laboratory, or pharmacy, or other person 8 licensed, registered, or otherwise lawfully permitted by the 9 United States or this State to distribute, dispense, conduct 10 research with respect to, administer or use in teaching or 11 chemical analysis, a controlled substance in the course of 12 professional practice or research.

(11) "Pre-printed prescription" means a written prescription upon which the designated drug has been indicated prior to the time of issuance; the term does not mean a written prescription that is individually generated by machine or computer in the prescriber's office.

(mm) "Prescriber" means a physician licensed to practice 18 branches, dentist, optometrist, 19 medicine in all its 20 prescribing psychologist licensed under Section 4.2 of the 21 Clinical Psychologist Licensing Act with prescriptive 22 authority delegated under Section 4.3 of the Clinical 23 Licensing Act, podiatric physician, Psychologist or veterinarian who issues a prescription, a physician assistant 24 25 who issues a prescription for a controlled substance in accordance with Section 303.05, a written delegation, and a 26

written supervision agreement required under Section 7.5 of the 1 2 Physician Assistant Practice Act of 1987, an advanced practice 3 nurse with prescriptive authority delegated under Section 65-40 of the Nurse Practice Act and in accordance with Section 4 5 303.05, a written delegation, and a written collaborative agreement under Section 65-35 of the Nurse Practice Act, or an 6 7 advanced practice nurse certified as a nurse practitioner, 8 nurse midwife, or clinical nurse specialist who has been 9 granted authority to prescribe by a hospital affiliate in 10 accordance with Section 65-45 of the Nurse Practice Act and in 11 accordance with Section 303.05.

12 (nn) "Prescription" means a written, facsimile, or oral 13 order, or an electronic order that complies with applicable 14 federal requirements, of a physician licensed to practice 15 medicine in all its branches, dentist, podiatric physician or 16 veterinarian for any controlled substance, of an optometrist in 17 accordance with Section 15.1 of the Illinois Optometric Practice Act of 1987, of a prescribing psychologist licensed 18 under Section 4.2 of the Clinical Psychologist Licensing Act 19 20 with prescriptive authority delegated under Section 4.3 of the Clinical Psychologist Licensing Act, of a physician assistant 21 22 for a controlled substance in accordance with Section 303.05, a 23 written delegation, and a written supervision agreement required under Section 7.5 of the Physician Assistant Practice 24 25 Act of 1987, of an advanced practice nurse with prescriptive 26 authority delegated under Section 65-40 of the Nurse Practice

Act who issues a prescription for a controlled substance in 1 2 accordance with Section 303.05, a written delegation, and a 3 written collaborative agreement under Section 65-35 of the Nurse Practice Act, or of an advanced practice nurse certified 4 5 as a nurse practitioner, nurse midwife, or clinical nurse specialist who has been granted authority to prescribe by a 6 hospital affiliate in accordance with Section 65-45 of the 7 Nurse Practice Act and in accordance with Section 303.05 when 8 9 required by law.

10 (nn-5) "Prescription Information Library" (PIL) means an 11 electronic library that contains reported controlled substance 12 data.

13 (nn-10) "Prescription Monitoring Program" (PMP) means the 14 entity that collects, tracks, and stores reported data on 15 controlled substances and select drugs pursuant to Section 316.

16 (oo) "Production" or "produce" means manufacture, 17 planting, cultivating, growing, or harvesting of a controlled 18 substance other than methamphetamine.

19 (pp) "Registrant" means every person who is required to 20 register under Section 302 of this Act.

21 (qq) "Registry number" means the number assigned to each 22 person authorized to handle controlled substances under the 23 laws of the United States and of this State.

(qq-5) "Secretary" means, as the context requires, either
 the Secretary of the Department or the Secretary of the
 Department of Financial and Professional Regulation, and the

HB3910 - 23 - LRB100 10675 RLC 20899 b

1 Secretary's designated agents.

(rr) "State" includes the State of Illinois and any state,
district, commonwealth, territory, insular possession thereof,
and any area subject to the legal authority of the United
States of America.

6 (rr-5) "Stimulant" means any drug that (i) causes an 7 overall excitation of central nervous system functions, (ii) 8 causes impaired consciousness and awareness, and (iii) can be 9 habit-forming or lead to a substance abuse problem, including 10 but not limited to amphetamines and their analogs, 11 methylphenidate and its analogs, cocaine, and phencyclidine 12 and its analogs.

(ss) "Ultimate user" means a person who lawfully possesses a controlled substance for his or her own use or for the use of member of his or her household or for administering to an animal owned by him or her or by a member of his or her household.

18 (Source: P.A. 98-214, eff. 8-9-13; 98-668, eff. 6-25-14; 19 98-756, eff. 7-16-14; 98-1111, eff. 8-26-14; 99-78, eff. 20 7-20-15; 99-173, eff. 7-29-15; 99-371, eff. 1-1-16; 99-480, eff. 9-9-15; 99-642, eff. 7-28-16.)

22 (720 ILCS 570/312) (from Ch. 56 1/2, par. 1312)

23 Sec. 312. Requirements for dispensing controlled24 substances.

25

(a) A practitioner, in good faith, may dispense a Schedule

II controlled substance, which is a narcotic drug listed in 1 2 Section 206 of this Act; or which contains any quantity of 3 amphetamine or methamphetamine, their salts, optical isomers or salts of optical isomers; phenmetrazine and its salts; or 4 5 pentazocine; and Schedule III, IV, or V controlled substances to any person upon a written or electronic prescription of any 6 7 prescriber, dated and signed by the person prescribing (or electronically validated in compliance with Section 311.5) on 8 9 the day when issued and bearing the name and address of the 10 patient for whom, or the owner of the animal for which the 11 controlled substance is dispensed, and the full name, address 12 and registry number under the laws of the United States relating to controlled substances of the prescriber, if he or 13 14 she is required by those laws to be registered. If the prescription is for an animal it shall state the species of 15 16 animal for which it is ordered. The practitioner filling the 17 prescription shall, unless otherwise permitted, write the date of filling and his or her own signature on the face of the 18 written prescription or, alternatively, shall indicate such 19 20 filling using a unique identifier as defined in paragraph (v) of Section 3 of the Pharmacy Practice Act. The written 21 22 prescription shall be retained on file by the practitioner who 23 filled it or pharmacy in which the prescription was filled for a period of 2 years, so as to be readily accessible for 24 25 inspection or removal by any officer or employee engaged in the enforcement of this Act. Whenever the practitioner's or 26

pharmacy's copy of any prescription is removed by an officer or 1 2 employee engaged in the enforcement of this Act, for the 3 purpose of investigation or as evidence, such officer or employee shall give to the practitioner or pharmacy a receipt 4 5 in lieu thereof. If the specific prescription is machine or computer generated and printed at the prescriber's office, the 6 date does not need to be handwritten. A prescription for a 7 Schedule II controlled substance shall not be issued for more 8 9 than a 30 day supply, except as provided in subsection (a-5), 10 and shall be valid for up to 90 days after the date of 11 issuance. A written prescription for Schedule III, IV or V 12 controlled substances shall not be filled or refilled more than 13 6 months after the date thereof or refilled more than 5 times 14 unless renewed, in writing, by the prescriber. A pharmacy shall 15 maintain a policy regarding the type of identification 16 necessary, if any, to receive a prescription in accordance with 17 State and federal law. The pharmacy must post such information where prescriptions are filled. 18

19 (a-5) Physicians may issue multiple prescriptions (3 20 sequential 30-day supplies) for the same Schedule II controlled 21 substance, authorizing up to a 90-day supply. Before 22 authorizing a 90-day supply of a Schedule II controlled 23 substance, the physician must meet the following conditions:

(1) Each separate prescription must be issued for a
 legitimate medical purpose by an individual physician
 acting in the usual course of professional practice.

1 (2) The individual physician must provide written 2 instructions on each prescription (other than the first 3 prescription, if the prescribing physician intends for the 4 prescription to be filled immediately) indicating the 5 earliest date on which a pharmacy may fill that 6 prescription.

7 (3) The physician shall document in the medical record
8 of a patient the medical necessity for the amount and
9 duration of the 3 sequential 30-day prescriptions for
10 Schedule II narcotics.

11 (b) In lieu of a written prescription required by this 12 Section, a pharmacist, in good faith, may dispense Schedule III, IV, or V substances to any person either upon receiving a 13 facsimile of a written, signed prescription transmitted by the 14 15 prescriber or the prescriber's agent or upon a lawful oral 16 prescription of a prescriber which oral prescription shall be 17 reduced promptly to writing by the pharmacist and such written memorandum thereof shall be dated on the day when such oral 18 prescription is received by the pharmacist and shall bear the 19 20 full name and address of the ultimate user for whom, or of the owner of the animal for which the controlled substance is 21 22 dispensed, and the full name, address, and registry number 23 under the law of the United States relating to controlled 24 substances of the prescriber prescribing if he or she is 25 required by those laws to be so registered, and the pharmacist 26 filling such oral prescription shall write the date of filling

- 27 - LRB100 10675 RLC 20899 b

and his or her own signature on the face of such written 1 2 memorandum thereof. The facsimile copy of the prescription or 3 written memorandum of the oral prescription shall be retained on file by the proprietor of the pharmacy in which it is filled 4 5 for a period of not less than two years, so as to be readily accessible for inspection by any officer or employee engaged in 6 7 the enforcement of this Act in the same manner as a written 8 prescription. The facsimile copy of the prescription or oral 9 prescription and the written memorandum thereof shall not be 10 filled or refilled more than 6 months after the date thereof or 11 be refilled more than 5 times, unless renewed, in writing, by 12 the prescriber.

13 for (C) Except any non-prescription targeted 14 methamphetamine precursor regulated by the Methamphetamine Precursor Control Act, a controlled substance included in 15 16 Schedule V shall not be distributed or dispensed other than for 17 a medical purpose and not for the purpose of evading this Act, and then: 18

(1) only personally by a person registered to dispense
a Schedule V controlled substance and then only to his or
her patients, or

(2) only personally by a pharmacist, and then only to a
person over 21 years of age who has identified himself or
herself to the pharmacist by means of 2 positive documents
of identification.

26

HB3910

(3) the dispenser shall record the name and address of

1 2 the purchaser, the name and quantity of the product, the date and time of the sale, and the dispenser's signature.

3 (4) no person shall purchase or be dispensed more than 120 milliliters or more than 120 grams of any Schedule V 4 substance which contains codeine, dihydrocodeine, or any 5 6 salts thereof, or ethylmorphine, or any salts thereof, in 7 any 96 hour period. The purchaser shall sign a form, 8 approved by the Department of Financial and Professional 9 Regulation, attesting that he or she has not purchased any 10 Schedule V controlled substances within the immediately 11 preceding 96 hours.

12

(5) (Blank).

13 (6) all records of purchases and sales shall be14 maintained for not less than 2 years.

15 (7) no person shall obtain or attempt to obtain within 16 any consecutive 96 hour period any Schedule V substances of 17 more than 120 milliliters or more than 120 grams containing 18 codeine, dihydrocodeine or any of its salts, or 19 ethylmorphine or any of its salts. Any person obtaining any 20 such preparations or combination of preparations in excess 21 of this limitation shall be in unlawful possession of such 22 controlled substance.

(8) a person qualified to dispense controlled
substances under this Act and registered thereunder shall
at no time maintain or keep in stock a quantity of Schedule
V controlled substances in excess of 4.5 liters for each

substance; a pharmacy shall at no time maintain or keep in 1 2 stock a quantity of Schedule V controlled substances as defined in excess of 4.5 liters for each substance, plus 3 the additional quantity of controlled substances necessary 4 5 to fill the largest number of prescription orders filled by that pharmacy for such controlled substances in any one 6 7 week in the previous year. These limitations shall not 8 apply to Schedule V controlled substances which Federal law 9 prohibits from being dispensed without a prescription.

10 (9) no person shall distribute or dispense butyl
11 nitrite for inhalation or other introduction into the human
12 body for euphoric or physical effect.

13 (d) Every practitioner shall keep a record or log of controlled substances received by him or her and a record of 14 15 all such controlled substances administered, dispensed or 16 professionally used by him or her otherwise than by 17 prescription. It shall, however, be sufficient compliance with this paragraph if any practitioner utilizing controlled 18 substances listed in Schedules III, IV and V shall keep a 19 20 record of all those substances dispensed and distributed by him or her other than those controlled substances which are 21 22 administered by the direct application of a controlled 23 substance, whether by injection, inhalation, ingestion, or any 24 other means to the body of a patient or research subject. A practitioner who dispenses, other than by administering, a 25 26 controlled substance in Schedule II, which is a narcotic drug

listed in Section 206 of this Act, or which contains any quantity of amphetamine or methamphetamine, their salts, optical isomers or salts of optical isomers, pentazocine, or methaqualone shall do so only upon the issuance of a written prescription blank or electronic prescription issued by a prescriber.

7 Whenever a manufacturer distributes a controlled (e) 8 substance in a package prepared by him or her, and whenever a 9 wholesale distributor distributes a controlled substance in a 10 package prepared by him or her or the manufacturer, he or she 11 shall securely affix to each package in which that substance is 12 contained a label showing in legible English the name and 13 address of the manufacturer, the distributor and the quantity, kind and form of controlled substance contained therein. No 14 15 person except a pharmacist and only for the purposes of filling 16 a prescription under this Act, shall alter, deface or remove 17 any label so affixed.

Whenever a practitioner dispenses any controlled 18 (f) 19 substance except a non-prescription Schedule V product or a 20 non-prescription targeted methamphetamine precursor regulated by the Methamphetamine Precursor Control Act, he or she shall 21 22 affix to the container in which such substance is sold or 23 dispensed, a label indicating the date of initial filling, the practitioner's name and address, the name of the patient, the 24 25 name of the prescriber, the directions for use and cautionary 26 statements, if any, contained in any prescription or required

by law, the proprietary name or names or the established name of the controlled substance, and the dosage and quantity, except as otherwise authorized by regulation by the Department of Financial and Professional Regulation. No person shall alter, deface or remove any label so affixed as long as the specific medication remains in the container.

7 (g) A person to whom or for whose use any controlled 8 substance has been prescribed or dispensed by a practitioner, 9 or other persons authorized under this Act, and the owner of 10 any animal for which such substance has been prescribed or 11 dispensed by a veterinarian, may lawfully possess such 12 substance only in the container in which it was delivered to 13 him or her by the person dispensing such substance.

The responsibility for the proper prescribing or 14 (h) 15 dispensing of controlled substances that are under the 16 prescriber's direct control is upon the prescriber. The 17 responsibility for the proper filling of a prescription for controlled substance drugs rests with the pharmacist. An order 18 purporting to be a prescription issued to any individual, which 19 20 is not in the regular course of professional treatment nor part of an authorized methadone maintenance program, 21 nor in 22 legitimate and authorized research instituted bv anv 23 accredited hospital, educational institution, charitable foundation, or federal, state or local governmental agency, and 24 25 which is intended to provide that individual with controlled substances sufficient to maintain that individual's or any 26

1 other individual's physical or psychological addiction, 2 habitual or customary use, dependence, or diversion of that 3 controlled substance is not a prescription within the meaning 4 and intent of this Act; and the person issuing it, shall be 5 subject to the penalties provided for violations of the law 6 relating to controlled substances.

7 (i) A prescriber shall not pre-print or cause to be 8 pre-printed a prescription for any controlled substance; nor 9 shall any practitioner issue, fill or cause to be issued or 10 filled, a pre-printed prescription for any controlled 11 substance.

12 (i-5) A prescriber may use a machine or electronic device 13 to individually generate a printed prescription, but the 14 prescriber is still required to affix his or her manual 15 signature.

16 (j) No person shall manufacture, dispense, deliver, 17 possess with intent to deliver, prescribe, or administer or cause to be administered under his or her direction any 18 anabolic steroid, for any use in humans other than the 19 20 treatment of disease in accordance with the order of a physician licensed to practice medicine in all its branches for 21 22 a valid medical purpose in the course of professional practice. 23 The use of anabolic steroids for the purpose of hormonal manipulation that is intended to increase muscle mass, strength 24 25 or weight without a medical necessity to do so, or for the 26 intended purpose of improving physical appearance or

1 performance in any form of exercise, sport, or game, is not a 2 valid medical purpose or in the course of professional 3 practice.

4 (k) Controlled substances may be mailed if all of the
5 following conditions are met:

6 (1) The controlled substances are not outwardly 7 dangerous and are not likely, of their own force, to cause 8 injury to a person's life or health.

9 (2) The inner container of a parcel containing 10 controlled substances must be marked and sealed as required 11 under this Act and its rules, and be placed in a plain 12 outer container or securely wrapped in plain paper.

13 (3) If the controlled substances consist of 14 prescription medicines, the inner container must be 15 labeled to show the name and address of the pharmacy or 16 practitioner dispensing the prescription.

17 (4) The outside wrapper or container must be free of18 markings that would indicate the nature of the contents.

19 (1) Notwithstanding any other provision of this Act to the 20 contrary, emergency medical services personnel may administer 21 Schedule II, III, IV, or V controlled substances to a person in 22 the scope of their employment without a written, electronic, or 23 oral prescription of a prescriber.

24 (Source: P.A. 99-78, eff. 7-20-15; 99-480, eff. 9-9-15.)